Skip to main content
. 2021 Oct 31;33(5):606–615. doi: 10.21147/j.issn.1000-9604.2021.05.07

Table 1. Patient and tumor characteristics.

Characteristics n (%) P
Training cohort (N=552) Validation cohort (N=252)
NCRT, neoadjuvant chemoradiotherapy; MRI, magnetic resonance imaging; EMVI, extramural venous invasion; CEA, carcinoma embryonic antigen; DTA, distance from inferior part of tumor to anal verge; DMRF, distance between the deepest tumor invasion and mesorectal fascia.
Centers
The Sixth Affiliated Hospital of Sun Yat-Sen University 226 (40.9)
Cancer Hospital Chinese Academy of Medical Sciences 175 (31.7)
Liaoning Province Cancer Hospital & Institute 151 (27.4)
Peking University Cancer Hospital 252 (100)
Age ( Inline graphic ) (year) 55.5±11.5 55.2±11.7 0.918
Sex 0.665
Male 366 (66.3) 171 (67.9)
Female 186 (33.7) 81 (32.1)
Pre-NCRT cT stage 0.132
cT3a/b 288 (52.2) 133 (52.8)
cT3c 211 (38.2) 84 (33.3)
cT3d 53 (9.6) 35 (13.9)
Pre-NCRT cN stage 0.835
cN0 103 (18.7) 51 (20.2)
cN1 118 (21.3) 55 (21.8)
cN2 331 (60.0) 146 (58.0)
Pre-NCRT MRI EMVI 0.901
Negative 377 (68.3) 171 (67.8)
Positive 175 (31.7) 81 (32.2)
Pre-NCRT CEA (ng/mL) ( Inline graphic ) 8.1±18.0 8.2±18.6 0.977
DTA (cm) 0.564
Upper (>10) 18 (3.3) 12 (4.8)
Middle (6−10) 252 (45.7) 111 (44.0)
Lower (0−5) 282 (51.1) 129 (51.2)
Operation 0.965
Miles 279 (50.6) 128 (50.8)
Dixon 253 (45.8) 114 (45.2)
Hartmann 20 (3.6) 10 (4.0)
Adjuvant chemotherapy 0.817
No 294 (53.3) 132 (52.4)
Yes 258 (46.7) 120 (47.6)
ypT stage 0.975
ypT0 112 (20.3) 49 (19.4)
ypT1 24 (4.3) 12 (4.8)
ypT2 154 (27.9) 73 (29.0)
ypT3 262 (47.5) 118 (46.8)
ypN stage 0.781
ypN0 401 (72.6) 186 (73.8)
ypN1 107 (19.4) 44 (17.5)
ypN2 44 (8.0) 22 (8.7)
DMRF (mm) 0.624
<7 484 (87.7) 224 (88.9)
≥7 68 (12.3) 28 (11.1)